The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Sanofi and GlaxoSmithKline are working together to create a COVID-19 vaccine with funding from HHS, the drugmakers said April 14. The drugmakers said they will combine technology Sanofi has used ...

Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organization's Covax initiative if the vaccine receives regulatory ...

Image Source: Zacks Investment Research. Sanofi Deal Breathes New Life Into NVAX Stock. Beginning next year, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

The U.S. government will pay drugmakers Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine, the companies announced Friday.

PARIS, May 14 (Reuters) - Sanofi chief executive Paul Hudson said on Thursday it was vital that any coronavirus vaccine reach all parts of the world, after angering the French government earlier ...